Capricor Therapeutics (NASDAQ:CAPR) Sees 6.6% Rise - Is It Still a Good Investment?

Shares of Capricor Therapeutics Inc (NASDAQ: CAPR) rose by 6.6% on Thursday, reaching a high of $13.30 before closing at $13.48. During the trading session, approximately 457,699 shares were exchanged, which is a significant decline of 66% compared to the average trading volume of 1,334,590 shares. The stock had finished the previous day at $12.65.

Latest Alerts on Capricor Therapeutics

Analysts Update Price Predictions

• MarketBeat Weekly Overview – 9/30 - 10/4

Recently, several analysts have provided their insights on Capricor's stock. HC Wainwright reaffirmed a "buy" rating and projected a price target of $77.00 for the shares. Additionally, Cantor Fitzgerald raised their price target from $25.00 to $30.00 while maintaining an "overweight" rating. Notably, one analyst has given the stock a sell rating, while six others have rated it as a buy. Currently, the average rating for Capricor Therapeutics is "Moderate Buy," with an average target price set at $34.50, according to MarketBeat.com.

In-Depth Analysis on Capricor Therapeutics

Capricor Therapeutics Trading Activity

• Significant Rise Over 100% - Future Potential?

Capricor boasts a market capitalization of $614.07 million, a P/E ratio of -12.74, and a beta of 4.08, indicating substantial volatility. The company's 50-day simple moving average stands at $14.37, while the 200-day moving average is $13.93.

Investor Activity in Capricor Therapeutics

Several institutional investors have adjusted their holdings in CAPR recently. For instance, UBS Asset Management acquired a new stake valued at approximately $462,000 during the fourth quarter. Similarly, Voloridge Investment Management invested around $1,678,000 in the same quarter. Woodline Partners took a new position worth $8,693,000, while Two Sigma Investments increased their stake by 223.6%, now holding 119,047 shares valued at $1,643,000 after acquiring an additional 82,254 shares. Lastly, Rafferty Asset Management also invested around $1,743,000 in Capricor. Overall, institutional investors control about 21.68% of Capricor Therapeutics' shares.

Overview of Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology firm dedicated to the discovery, development, and commercialization of innovative biological therapies for rare diseases. The company's lead candidate, CAP-1002, is an allogeneic cell therapy currently under clinical investigation for treating Duchenne muscular dystrophy.

Additional Insights

• Five alternative stocks to consider over Capricor Therapeutics
• The importance of brokerage ratings in stock selection
• Occidental Petroleum reaches a 52-week low: To buy, sell, or hold?
• Understanding Special Purpose Acquisition Companies (SPACs)
• Super Micro Computer achieves NASDAQ compliance - Should you invest?
• Opportunities in discounted dividend growth stocks
• Tendency of Taiwan Semiconductor's $100 billion investment: What’s next for chipmakers?

This report was drafted through automated systems utilizing financial data to produce timely and accurate information. The content was reviewed by a dedicated editorial team before its release. Any inquiries or feedback can be directed to specified contact channels.

Should You Invest $1,000 in Capricor Therapeutics Now?

Before making any investment in Capricor Therapeutics, it's crucial to consider various factors. Research analysts noted that although Capricor holds a Buy rating, there are five stocks they find more compelling at the moment.

Discover which five stocks these analysts suggest for potential investment.

Capricor, Therapeutics, Stocks